Key result
Epicardial catheter ablation for ventricular tachycardia in ischemic cardiomyopathy achieved a 73% VT-free survival at 35 months, comparable to 66% with endocardial-only ablation.
Why the study?
Does epicardial catheter ablation provide comparable long-term VT-free survival to endocardial-only ablation in patients with ischemic cardiomyopathy?
Observational (n=57)
No
Does epicardial catheter ablation provide comparable long-term VT-free survival to endocardial-only ablation in patients with ischemic cardiomyopathy?
Epicardial catheter ablation for ventricular tachycardia in ischemic cardiomyopathy is effective, achieving long-term arrhythmia control comparable to endocardial-only ablation.
Answers are grounded in this paper and cite their sources.
Epicardial ablation was associated with comparable VT-free survival in ICM; hypothesis-generating and requires randomized confirmation.
Introduction The characteristics of the epicardial (EPI) substrate responsible for ventricular tachycardia (VT) in ischemic cardiomyopathy (ICM) are undefined, and data on the long‐term outcomes of EPI catheter ablation limited. We evaluated the prevalence, electrophysiologic features, and outcomes of catheter ablation of EPI VT in ICM. Methods and Results From December 2010 to June 2013, a total of 13 of 93 (14%) patients with ICM underwent catheter ablation at our institution and had conclusive evidence of critical EPI substrate demonstrated to participate in VT with activation, entrainment and/or pace mapping during sinus rhythm (two other patients underwent EPI mapping but had no optimal ablation targets). The electrophysiologic substrate characteristics and activation/entrainment mapping data were compared with a reference group of ICM patients without evidence of critical EPI substrate ( N = 44), defined as a complete procedural success (noninducibility of any VT at programmed stimulation) after endocardial (ENDO)‐only ablation. Patients with failed EPI access ( N = 2) or history of cardiac surgery ( N = 92) were excluded from the study. All 13 patients had evidence of abnormal EPI substrate with fractionated/late/split electrograms and low‐bipolar voltage areas. The critical VT ablation sites were all located within the EPI bipolar “dense” scar (<1.0 mV) opposite the ENDO bipolar scar in 77% of cases and extending beyond the ENDO bipolar scar (within the ENDO unipolar low‐voltage area) in the remaining patients. Compared with the reference ENDO‐only group, patients with EPI VT had a smaller ENDO bipolar scar area, 54.0 (37.1‐84) vs 86.7 (55.6‐112) cm 2 ; P = 0.0159, with a similar extent of ENDO unipolar low voltage. No other substrate characteristics or location differed between the two groups. After 35.2 ± 24.2 months of follow‐up, VT‐free survival was 73% in patients with EPI VT compared with 66% in the ENDO‐only group (log‐rank P = 0.56). Conclusions The presence of the critical EPI substrate responsible for VT can be demonstrated in at least 14% of patients with ICM. The majority of EPI critical ablation sites are distributed opposite the ENDO bipolar scar area and catheter ablation is effective in achieving long‐term arrhythmia control.
No takes yet. Share an insight, caveat, or question.
Hayashi et al. (2018) conducted an observational in Ischemic cardiomyopathy with ventricular tachycardia (n=57). Epicardial catheter ablation vs. Endocardial-only ablation was evaluated on VT-free survival (p=0.56). Epicardial catheter ablation for ventricular tachycardia in ischemic cardiomyopathy achieved a 73% VT-free survival at 35 months, comparable to 66% with endocardial-only ablation.
Synapse has enriched 10 related papers. Consider them for comparative context: